Guardant Health (GH) EBITDA (2017 - 2026)

Guardant Health has disclosed EBITDA across 10 years of filings, most recently posting -$129.1 million for Q2 2026.

• In Q2 2026, EBITDA fell 21.34% year-over-year to -$129.1 million; the TTM figure through Jun 2026 stood at -$470.3 million (down 2.07% YoY), while the FY2025 annual figure was -$437.2 million, up 1.43% from the prior year.
• EBITDA came in at -$129.1 million for Q2 2026 at Guardant Health, down from -$121.4 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$99.0 million in Q3 2025 to a low of -$197.5 million in Q4 2023.
• Average EBITDA over 5 years is -$124.5 million, with a median of -$121.1 million recorded in 2025.
• Year-over-year, EBITDA sank 48.79% in 2022 and soared 36.22% in 2024.
• Over 5 years, EBITDA stood at -$146.1 million in 2022, then plunged by 35.17% to -$197.5 million in 2023, then soared by 36.22% to -$126.0 million in 2024, then rose by 4.1% to -$120.8 million in 2025, then declined by 6.88% to -$129.1 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$129.1 million in Q2 2026, -$121.4 million in Q1 2026, and -$120.8 million in Q4 2025.